Key Highlights

  • CTSO is trading up 14.21% at $6.11 on October 22, versus a prior close of $5.35.
  • Market capitalization was $16.86 million at the prior close, and about $19.3 million at today's price, calculated.
  • Second-quarter revenue was $9.6 million, flat from a year earlier, with a gross margin of 73%.
  • Cash, equivalents and restricted cash were $5.9 million at June 30, and quarterly cash burn fell to $0.4 million.
  • A 1-for-20 reverse stock split took effect on September 8.

Why Is CytoSorbents Stock Surging on October 22?

CytoSorbents (NASDAQ:CTSO) is trading up 14.21% at $6.11 on October 22. The most recent company-level event identified was the initiation of coverage by WBB Securities with a Speculative Buy rating, reported about a day earlier. No company press release was identified for the session itself.

What investors may be missing is the share structure. A 1-for-20 reverse split took effect on September 8, leaving a market capitalization of $16.86 million at the prior close of $5.35 and a free float of about 2.64 million shares. A small float can amplify moves in either direction. Trading was also halted pending news around the time of the split, and the shares have since moved by wide margins from session to session.

What Does CytoSorbents Do, and Where Are the Results Heading?

CytoSorbents develops blood purification technology, led by the CytoSorb device used in critical care and cardiac surgery. Second-quarter revenue on August 6 was $9.6 million, flat from a year earlier, while gross margin improved to 73% from 71% a year earlier and 69% in the first quarter.

The operating loss narrowed 27% to $2.6 million, and the net loss was $4.4 million, or $0.07 per share, against net income of $1.9 million a year earlier, a swing the company attributed mainly to non-cash foreign currency translation effects. Adjusted EBITDA loss improved 38% to $1.6 million.

How Tight Is the Cash Position Ahead of the Nasdaq Deadline?

Cash, equivalents and restricted cash were $5.9 million at June 30. Quarterly cash burn fell to $0.4 million, including $0.2 million of restructuring payments. Management listed operating cash flow breakeven, a return to profitable growth for CytoSorb, FDA approval for DrugSorb-ATR and strategic options for HemoDefend-BGA as its value drivers, with no numeric guidance.

On September 22 Nasdaq confirmed that the shares had met the $1.00 minimum bid price after 10 consecutive trading days at or above that level. The company must still regain full Nasdaq Capital Market compliance, including the minimum market value of listed securities, by December 28, 2026.

What Role Does DrugSorb-ATR Play in the Next Chapter?

The company is preparing a new De Novo submission for DrugSorb-ATR in patients taking ticagrelor, planned for early 2027 under Breakthrough Device designation. Two FDA pre-submission meetings gave feedback on separate pathways for ticagrelor and direct oral anticoagulant removal. Real-world data from about 198 CytoSorb-treated patients will anchor the filing, bringing the treated dataset to roughly 250.

The company also scheduled data presentations at the EACTS meeting on October 7 to 10 and the ESICM congress on October 10 to 14. The December 28 compliance deadline and the early 2027 submission are the dates that matter most from here.